Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Glucose Health's enterprise value is $10.44 Mil.
Glucose Health's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.05 Mil. Therefore, Glucose Health's EV-to-EBITDA for today is -217.42.
The historical rank and industry rank for Glucose Health's EV-to-EBITDA or its related term are showing as below:
GLUC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -217.42 Med: 0 Max: 0
Current: -217.42
GLUC's EV-to-EBITDA is not ranked
in the Consumer Packaged Goods industry.
Industry Median: 9.25
vs GLUC: -217.42
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Glucose Health (OTCPK:GLUC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Glucose Health's PE Ratio (TTM) for today is calculated as:
Glucose Health's share price for today is $0.39.
Glucose Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Glucose Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Glucose Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glucose Health EV-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Glucose Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Glucose Health's EV-to-EBITDA falls into.
Glucose Health's current Enterprise Value is $10.44 Mil.
Glucose Health's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glucose Health (GLUC) has a EV-to-EBITDA of -217.42 as of Sep. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Glucose Health.
Is Glucose Health's EV-to-EBITDA too high?
Glucose Health's current EV-to-EBITDA is -217.42. Overall, Glucose Health has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Glucose Health's EV-to-EBITDA compare to RTON and BDPT?
Glucose Health's EV-to-EBITDA of -217.42 can be compared against companies in the Consumer Packaged Goods industry. The industry median EV-to-EBITDA is 9.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Consumer Packaged Goods company?
The median EV-to-EBITDA among Consumer Packaged Goods companies is 9.25, based on 1,659 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Glucose Health. For the Consumer Packaged Goods industry, the median EV-to-EBITDA is 9.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glucose Health's current EV-to-EBITDA is -217.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glucose Health stock overvalued right now?
Glucose Health (GLUC) has a current EV-to-EBITDA of -217.42. The current EV-to-EBITDA is -217.42. Glucose Health's overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Glucose Health (GLUC), the current EV-to-EBITDA is -217.42 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Glucose Health Inc is an own-label distributor of nutritional beverages. Its niche is the formulation, manufacturing, marketing, and distribution of soluble fiber-infused nutritional beverages. The Company has identified two underserved consumer markets and has launched two brands to serve these markets, which are GlucoDown and FIBER UP. The Company currently has one single operating and reporting segment, which is the manufacturing and distribution of nutritional beverages. It generates all of its revenue from sales of nutritional beverages. The beverages are sold through the Company's website as well as through retailers.
38GF Score
Get the complete analysis for GLUC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLUC has been successfully added to your 
